Jeffrey A. Brent, MD, PhD, FACMT Distinguished Clinical Professor of MedicineUniversity of Colorado Schools of Medicine and Public HealthAurora, CO
Dr. Jeffrey Brent is a Distinguished Clinical Professor of Medicine, Emergency Medicine, and Pediatrics at the University of Colorado, School of Medicine, and Clinical Professor of Environmental and Occupational Medicine at the School of Public Health. He is the recipient of numerous honors and awards. Dr. Brent is the senior editor of Critical Care Toxicology: The Diagnosis and Treatment of the Acutely Poisoned Patient, is former Editor of Toxicological Reviews, and a member of the Editorial Board of Clinical Toxicology. He is a former President of the AACT and a former Board member of the ACMT. Dr. Brent’s areas of research are multi-center collaborations - specifically the development and application of the ToxIC network and Registry, adverse effects of metal-on-metal hip implants, effects of synthetic drugs of abuse, chemical threat agents, the role of lipid resuscitation therapy and and the epidemiology of poisonings in infants, children and pregnancy. In addition to his M.D., Dr. Brent holds a Ph.D. in biochemistry.
Judge Mary A. Celeste (ret.)
Judge Mary A. Celeste (ret.) sat on the Denver County Court bench where she was the Presiding Judge 2009 and 2010; the first woman to hold that position and was the co-founder of the Denver County Court Sobriety Court. She is the current education co-chair for the IALGT Judges; chair-elect ABA National Conference of Specialized Courts and Faculty for the National Center for DWI Courts (NCDC). She has served as the President of the American Judge’s Association and the Colorado Women’s Bar Association Foundation, and, as the National Highway Traffic Safety Administration (NHTSA) Judicial Outreach Liaison. She has written many articles and is a national speaker and expert on the topics of marijuana and alcohol/drug impaired driving. She has presented to NADCP, APPA, AJA, ABA, NHTSA, Lifesavers, Pennsylvania DUI Association, Michigan and Louisiana Association of Drug Court Professionals and to judges and other drug court professionals in the States of Colorado, Florida, Pennsylvania, Michigan, Nevada, Texas, Utah, and, Wyoming.
James R. Gill, MD
Chief Medical Examiner
State of Connecticut
Dr. Gill is the Chief Medical Examiner for the State of Connecticut and a Clinical Assistant Professor in the Department of Pathology at Yale. He is a graduate of M.I.T. and the University of Connecticut School of Medicine. He did his pathology training at Yale and Memorial Sloan-Kettering Cancer Center and his forensic pathology training in New York City. He is board certified in anatomic and forensic pathology. Prior to Connecticut, he was the Deputy Chief Medical Examiner for Bronx County in New York City. He has published numerous scientific articles and book chapters on a variety of forensic pathology and toxicology topics.
Christopher Hoyte, MDAssistant Professor, Emergency MedicineUniversity of Colorado School of MedicineAurora, CO
Christopher Hoyte, MD is an Assistant Professor in the Department of Emergency Medicine and Section of Medical Toxicology at the University of Colorado School of Medicine. I am the Fellowship Director of the medical toxicology fellowship at the Rocky Mountain Poison and Drug Center in Denver, CO. I am also the Associate Medical Director of the Rocky Mountain Poison Center. I graduated with a AB in Molecular Biology from Princeton University and then completed a Doctorate of Medicine at the University of Medicine and Dentistry of New Jersey. I completed my Emergency Medicine residency training at the Cook County Hospital in Chicago, IL and then a medical toxicology fellowship at the Rocky Mountain Poison and Drug Center. I am the Medical Director of the Medical Toxicology Clinic at the University of Colorado Hospital.
Marilyn A. Huestis, PhDSenior Investigator, Chief, Chemistry and Drug Metabolism SectionNational Institute on Drug Abuse, National Institutes of HealthBethesda, MD
Marilyn A. Huestis, PhD is a tenured senior investigator and Chief, Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health and Adjunct Professor in the Department of Epidemiology and Preventive Medicine, School of Medicine, University of Maryland. She thoroughly enjoys mentoring doctoral students in Toxicology, has to date directly overseen the research of 16 distinguished new toxicologists, and currently has 2 students pursuing their dissertation research. Her research program seeks to discover mechanisms of action of cannabinoid agonists and antagonists, effects of in utero drug exposure, and the neurobiology and pharmacokinetics of novel psychoactive substances, the emerging face of drug abuse. Professor Huestis is focused on new medication targets for cannabis dependence, including oral tetrahydrocannabinol (THC) and Sativex, a 1:1 ratio of tetrahydrocannabinol and cannabidiol. She is interested in the disposition of drugs and metabolites in a wide variety of biological fluids and tissues following controlled drug administration; data that provide a scientific database for interpreting drug concentrations in alternative matrices. Recently, Professor Huestis and colleagues documented that CB1-cannabinoid receptors are significantly down regulated in specific brain regions in chronic daily cannabis smokers, but these receptors significantly increased with sustained cannabis abstinence. Residual active cannabinoids could be quantified for up to 30 days in chronic smokers during sustained abstinence and, furthermore, psychomotor impairment was documented in these same subjects for at least 21 days. An area of special interest for Professor Huestis is investigating the effects of in utero drug exposure on child development and whether concentrations of drugs and/or metabolites in meconium predict adverse outcomes of in utero drug exposure. She has published 388 peer-reviewed manuscripts and book chapters and more than 500 abstracts were presented at national and international meetings. Professor Huestis received a bachelor's degree in biochemistry from Mount Holyoke College (cum laude), a master's degree in clinical chemistry from the University of New Mexico (with honors), and a doctoral degree in toxicology from the University of Maryland (with honors). Professor Huestis received a Doctor Honoris Causa from the Faculty of Medicine, University of Helsinki in Finland in 2010. Other important awards include, Distinguished Fellow Award from the American Academy of Forensic Sciences (AAFS) in 2015, The International Association of Forensic Toxicologists (TIAFT) Alan Curry Award in 2010, the American Association for Clinical Chemistry Outstanding Contributions in a Selected Area of Research Award in 2008, the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Irving Sunshine Award in 2007, the AAFS Rolla N. Harger Award in 2005, and the Irving Sunshine Award for Outstanding Research in Forensic Toxicology in 1992. The journal Clinical Chemistry featured her as an “Inspiring Mind”. She currently serves on the new National Commission on Forensic Sciences, and the Organization of Scientific Area Committee on Toxicology, World Anti-doping Agency’s Prohibited List Committee, the Scientific Working Group on Toxicology (SWG-TOX), Transportation Research Board Committee on Alcohol and Other Drugs, and the National Safety Council’s Alcohol, Drugs and Impairment Division Executive Board. Professor Huestis is past president of the Society of Forensic Toxicologists, past Chair of the Toxicology Section of the American Academy of Forensic Sciences, and the first woman president of The International Association of Forensic Toxicologists.
Robert D. Johnson, PhD, DABFT
Tarrant County Medical Examiner's Office
Ft. Worth, TX
Dr. Johnson earned a Ph.D in analytical chemistry from The University of Oklahoma. Certified as a Fellow by the American Board of Forensic Toxicology, he joined the Tarrant County Medical Examiner's Office as the chief toxicologist in 2011. Prior to joining the ME's office he worked for 10 years as a senior research chemist at the Federal Aviation Administration's Civil Aerospace Medical Institute in Oklahoma City. Dr. Johnson is active in the Society of Forensic Toxicologists, the American Academy of Forensic Sciences and the Southwestern Association of Toxicologists. He has published more than 50 scientific articles.
Michael J. Kosnett, MD, MPH, FACMTAssociate Clinical Professor, Clinical Pharmacology & ToxicologyUniversity of Colorado School of MedicineColorado School of Public HealthDenver, CO
Dr. Kosnett is an Associate Clinical Professor in the Division of Clinical Pharmacology and Toxicology at the University of Colorado School of Medicine, an Associate Adjunct Professor in the Department of Environmental and Occupational Health at the Colorado School of Public Health, and an Attending Physician at the Rocky Mountain Poison and Drug Center. He is board certified in internal medicine, preventive medicine (occupational medicine) and medical toxicology. Dr. Kosnett has held numerous leadership positions and national appointments as a medical toxicologist, including service as President of the American College of Medical Toxicology, member of the Committee on Toxicology of the National Research Council of the National Academy of Sciences, and consultant for the US EPA, the Department of Defense, CDC, Agency for Toxic Substances and Disease Registry, and the World Health Organization.
Recently in Colorado, Dr. Kosnett has been extensively engaged in public health efforts to reduce accidental pediatric exposures to cannabis products by educating regulators and stakeholders on the preventive value of child-resistant packaging. He recently served on the Department of Revenue Marijuana Enforcement Division (DOR/MED) Workgroup on HB14-1361 (Equivalencies) and HB14-1366 (Identifiable Retail Edibles), the Colorado Department of Public Health and Environment (CDPHE) Pediatric Exposure Prevention Guidelines Committee, and the DOR/MED Retail Marijuana Product Potency and Serving Size Working Group. He is a technical consultant to the CDPHE Retail Marijuana Public Health Advisory Committee on the pharmacology of cannabinoids. Dr. Kosnett has also offered scientific consultation to multiple stakeholders regarding health risks posed by pesticide residues in dried cannabis flowers, extracts and edibles.
Kenneth W. Kulig, MD, FACMT
Dr. Ken Kulig is a graduate of Wayne State University Medical School, the Emergency Medicine Residency at Denver Health, and the Fellowship at Rocky Mountain Poison Center. He was Director of that Toxicology Fellowship for 10 years when he became one of the founding partners of Toxicology Associates, Prof LLC in Denver in 1995, which sees toxicology patients in three Denver area hospitals. He is past president of the medical staff of Porter Adventist Hospital, chair of P & T, chair of patient safety of the Board, and has been involved in numerous medication safety initiatives locally and nationally. He has over 100 publications and peer reviews for multiple scientific journals and is co-editor of the toxicology section of the Journal of Emergency Medicine. His primary interests are ICU patient care including their spiritual needs, inpatient and outpatient medication safety, drug allergy communication, and medical staff issues such as credentialing and peer review.
Charles McKay, MD
University of Connecticut School of Medicine
Dr. McKay is a medical toxicologist at Hartford Hospital and the University of Connecticut School of Medicine, where he is an Associate Professor of Emergency Medicine. He is a diplomat of the ABMT and the ABMS Toxicology Subboard with primary residency and board in Internal Medicine and Emergency Medicine. He is the Associate Medical Director of the Connecticut Poison Control Center and participates in toxicology consult services at Hartford Hospital and Connecticut Children’s Medical Center (CCMC). As Medical Director of Occupational Health Services for Hartford Hospital and CCMC, he also evaluates questions of workplace safety and toxic exposure for 9,000 employees.
He has served on the ACMT Board of Directors since 2007 and is currently VIce-President. Dr. McKay is active in medical legal consultation, addressing issues of interpretation of laboratory studies and clinical impairment determination. He is active in ACMT"s educational efforts, coordinating Chemical Agents of Opportunity biopreparedness courses and participating in the management of the pediatric environmental health activities of the ATSDR-funded Pediatric Environmental Health Specialty Unity (PEHSU) program.
Andrew Monte, MD
Assistant Professor, Emergency Medicine
University of Colorado School of Medicine
Dr. Andrew A. Monte is an Emergency Medlclne and Medical Toxicology physician at the University of Colorado School of Medicine. He serves on the faculty at the Rocky Mountain Poison & Drug Center. Dr. Monte's research focuses on precision medicine and drugs of abuse. He works closely with the Colorado Department of Public Health and Environment on the Retail Marijuana Public Health Advisory Committee. This group is tasked with reviewing the scientific evidence on the public health implications of marijuana use in order to make policy and research recommendations to the Colorado legislature. He is considered a National expert on the health implications of cannabinoid use and has published and lectured widely on the topic.
Lewis Nelson, MD, FACMT
New York University School of Medicine
New York, NY
Dr. Nelson is currently a Professor of Emergency Medicine at New York University School of Medicine, and is an attending physician at both NYU Medical Center and Bellevue Hospital. He is the Director of the Fellowship in Medical Toxicology at New York University School of Medicine and the New York City Poison Control Center. He is a former President of the American College of Medical Toxicology and has served in various consultative roles with FDA, CDC, and DHS. He is an editor of Goldfrank’s Toxicologic Emergencies, now in its 10th Edition, a major textbook in the field of medical toxicology. He has published over 130 peer-reviewed publications and book chapters, and presents frequently at national and international meetings. The focus of his publications and presentations are medication-related adverse effects, chemical terrorism, and toxicity of abused drugs.
Christian Sederberg, Esq.
Partner, Founding Member
Christian Sederberg, Esq., is a partner and founding member of Vicente Sederberg LLC. After graduating from the University of Colorado School of Law, Christian focused his practice on representing businesses with a primary focus on real estate, private equity, commercial, and corporate transactions. Since the inception of Colorado's state regulated medical marijuana program, Christian and the firm have provided a wide range of real estate, transactional and regulatory assistance to the marijuana community. Christian was also an integral part of Colorado's Amendment 64 campaign, acting as core volunteer for the campaign, representing the campaign on Governor Hickenlooper's Amendment 64 Implementation Task Force, and leading the campaign's legislative implementation team in the Colorado legislature by coordinating the implementation of the Colorado legislative and regulatory structure related to adultuse marijuana. Christian sat on the executive committee of the Committee for Responsible Regulation, which coordinated the campaign to establish statewide excise and sales taxes on the sale of adultuse marijuana in Colorado.
Mark K. Su, MD, MPHClinical Associate Professor, Emergency MedicineNew York University School of MedicineNew York, NY
Dr. Su is currently the Director of the New York City Poison Control Center and an attending physician in the NYU/Bellevue Hospital Center Emergency Department. He is a graduate of the State University of New York Downstate Medical Center and Columbia University Mailman School of Public Health. He completed his Emergency Medicine training at SUNY-Downstate Medical Center/Kings County Hospital Center in Brooklyn, NY and Fellowship Training in Medical Toxicology at the New York City Poison Control Center. His current research interests focus mostly on synthetic cannabinoids and the epidemiology of poisoning.
Sarah Urfer, MS, D-ABFT-FT
ChemaTox Laboratory, Inc.
Sarah received her B.A. in Biochemistry, with a minor in Chemistry, from the University of Colorado Boulder in 2005 where she graduated with honors. Sarah received her M.S. in Forensic Science from the University of Illinois Chicago in 2006. After the completion of her M.S. Sarah was hired by ChemaTox Laboratory, Inc. where she became the Laboratory Director. At ChemaTox Sarah specializes in forensic and clinical toxicology analysis and interpretation for prosecution, defense, and civil attorneys. She is responsible for expert testimony in forensic toxicology, continuing education of analysts, method development, and overseeing the QA/QC program. She is a board certified Diplomate of The American Board of Forensic Toxicology (D-ABFT-FT). She has been qualified over 240 times as an expert in forensic toxicology.
Sarah specializes in impairment relating to the ability to operate a motor vehicle. She is a member of a number of forensic science professional organizations including the Society of Forensic Toxicologists (SOFT), The American Academy of Forensic Sciences (AAFS), The International Association of Forensic Toxicologists (TIAFT), California Association of Toxicologists (CAT), and National Association of Medical Examiners (NAME). Sarah is the chair of the SOFT Young Forensic Toxicologists (YFT) committee, and a member of the National Safety Council (Alcohol, Drugs and Impairment Division).
Sarah was invited to give expert testimony for Colorado Senate Committees regarding the proposed DUID THC per se bills introduced in Colorado in 2011 and 2012. Sarah frequently presents on various topics in forensic toxicology but has particular interest in zolpidem, and THC driving cases. Sarah has published on the topic of THC DUID testing and cases in Colorado.
George Sam Wang, MDAssistant Professor, PediatricsUniversity of Colorado School of MedicineAurora, CO
Dr. Wang, completed his pediatric residency and pediatric emergency medicine fellowship at Children's Hospital Colorado/Anschutz Medical Campus, and his medical toxicology fellowship at the Rocky Mountain Poison and Drug Center at Denver Health. He is an Assistant Professor of Pediatrics at Children's Hospital Colorado/Anschutz Medical Campus where he is a PEM and toxicology attending.
Paul Wax, MD, FACMT
American College of Medical Toxicology
Dr. Paul M. Wax is the Executive Director of the American College of Medical Toxicology. He received his B.A from Dartmouth College, his M.D. from the Mount Sinai School of Medicine, his Emergency Medicine training at the UCLA Hospitals, and his Medical Toxicology training at Bellevue Medicine Center / New York University. He is Board-certified in both Medical Toxicology and Emergency Medicine, and is a Fellow of the American College of Medical Toxicology. Along with his part time role as the Executive Director of ACMT, Dr. Wax is a Clinical Professor in Surgery (Emergency Medicine) at the University of Texas, Southwestern School of Medicine where he is a member of the Section of Medical Toxicology and Director of the Medical Toxicology Clinic. Before joining ACMT in 2008 as its Executive Director, and the University of Texas Southwestern in 2006 as a part-time faculty member, Dr. Wax had faculty appointments in the Departments of Emergency Medicine at the University of Rochester School of Medicine from 1991-2001 and the University of Arizona School of Medicine from 2001-2006. Dr. Wax previously served on the Board of Directors of ACMT from 1998-2008 serving as ACMT President from 2006-2008. During this tenure he chaired the ACMT Education Committee from 1998-2002. From 2002-2006 Dr. Wax served as the National Director of ACMT's Consultation Network to support the ATSDR Regional Offices and was co-founder of ACMT’s Chemical Agent of Opportunity course. From 1997-2006 Dr. Wax also served as one of the American Board of Emergency Medicine’s appointee’s on the Medical Toxicology Subboard. During this time Dr. Wax served as Editor of the Medical Toxicology Board Certification Examination as well as Chairman of the Subboard, and was also the primary author of the 2004 Core Content of Medical Toxicology. Dr. Wax has also served as a consultant to the Centers for Disease Control NCEH’s Division of Laboratory Sciences and was a member of NCEH/ATSDR Board of Scientific Counselors from 2006-2008.